LILRB1 and cancer: Third, as this subset, in contrast to KIR+ and NKG2A+ expanded NK cells, has potent ADCC capacity and at the same time can overcome inhibition by HLA class I when triggered by CD16, LIR‐1+ expanded NK cells are attractive to explore in cancer immunotherapy protocols involving antitumor antibodies in both autologous and allogeneic settings.